Matt Mamak, Robyn Downing, Laura Giambalvo, Bryan Skelton, and Kirk Ekena are noted for representing OncoSec Medical Incorporated in a $42 million public offering of common stock.
In the News February 3, 2021
Global Legal Chronicle | OncoSec Medical’s $42 Million Shares Offering
Phone: +1 212 210 1256
Phone: +1 212 210 9470
Phone: +1 919 862 2241
Senior Patent Agent
Phone: +1 919 862 2266
Related News & Insights
Press Release February 1, 2021OncoSec Medical Closes $42 Million Public Offering of Common StockAlston & Bird client OncoSec Medical Incorporated, a late-stage biotechnology company, has closed a public offering of common stock that raised approximately $42 million.
In the News March 17, 2020Global Legal Chronicle | Alpha Holdings, Inc. v. OncoSec Medical Incorporated, et al.Brett Jaffe, Joe Tully, Matt Mamak, Dennis Garris, Dave Brown, Mark McElreath, James Sullivan, Gerard Catalanello, Jim Vincequerra, Bryan Skelton, and Gidon Caine are noted for successfully representing OncoSec Medical Inc. in a putative shareholder class action.
Press Release February 8, 2022Nuvectis Pharma Closes $16 Million Initial Public Offering of Common StockAlston & Bird client Nuvectis Pharma Inc., an oncology-focused biopharmaceutical company based in Fort Lee, NJ, has announced the closing of its initial public offering (IPO) of 3.2 million shares of common stock at a price of $5 per share, for gross proceeds of $16 million before deducting underwriting discounts and offering expenses. All shares of common stock were offered by Nuvectis.
In the News May 4, 2020Law360, The Deal, Global Legal Chronicle | Menarini to Buy Stemline TherapeuticsMatt Mamak, Justin Howard, Mark McElreath, Robyn Downing, Natalie Clayton, Maddy Byrd, Mike Stevens, and Brendan Caroll are noted for representing Stemline Therapeutics in its $677 million acquisition by Menarini Group.
Press Release March 13, 2020OncoSec Defeats Shareholder’s Attempt to Enjoin $30 Million TransactionAlston & Bird scored a decisive victory in Nevada state court last week by securing the dismissal with prejudice of a putative shareholder class action asserted against client OncoSec Medical Incorporated and its board of directors.